• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down2.92% Nasdaq Down3.00%

    Biocept, Inc. (BIOC)

    -NasdaqCM
    1.98 Down 0.03(1.49%) 3:53PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Biocept, Inc.
    5810 Nancy Ridge Drive
    San Diego, CA 92121
    United States - Map
    Phone: 858-320-8200
    Fax: 858-320-8225
    Website: http://www.biocept.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Medical Laboratories & Research
    Full Time Employees:42

    Business Summary 

    Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options; OncoCEE-LU, a test for non-small cell lung cancer; and OncoCEE-GA for gastric cancer. The company is also developing other OncoCEE CTC tests, including OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma, as well as CEE-Selector, a sequencing application for various cancer types. It sells its cancer diagnostic tests directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. The company was founded in 1997 and is headquartered in San Diego, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biocept, Inc.

    Key Executives 
     PayExercised
    Mr. Michael W. Nall , 52
    Chief Exec. Officer, Pres and Director
    549.00K0.00
    Mr. Raaj Trivedi , 42
    VP of Commercial Operations
    211.00K0.00
    Dr. Soonkap Hahn Ph.D.,
    Founder
    N/AN/A
    Mr. Mark G. Foletta CPA, 54
    Interim Chief Financial Officer
    N/AN/A
    Mr. Pavel Tsinberg M.S.E,
    Director of Technology Devel.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders